Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyanosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Cyanosis. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2014-000865-34 Sponsor Protocol Number: AC-065C202 Start Date*: 2014-09-16
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-center, double-blind, randomized, placebo-controlled, parallel group, exploratory Phase 2 study to assess efficacy and safety of selexipag in adult subjects with Raynaud's Phenomenon second...
    Medical condition: Raynaud's Phenomenon secondary to Systemic Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019009-40 Sponsor Protocol Number: A7331010 Start Date*: 2010-07-08
    Sponsor Name:Pfizer, S.A.
    Full Title: Estudio clínico de Fase 2A, multicéntrico aleatorizado, doble ciego, controlado con placebo y con un fármaco activo, de diseño cruzado con dos cohortes y dos dosis, para la evaluación de la eficaci...
    Medical condition: Tratamiento del vasospasmo en el fenómeno de Raynaud primario y secundario.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037912 Raynaud's phenomenon LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) CZ (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-001899-38 Sponsor Protocol Number: BAY63-2521/16787 Start Date*: 2013-07-29
    Sponsor Name:Bayer HealthCare AG
    Full Title: Single dose, double-blind, placebo-controlled, single center, randomized cross-over study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after o...
    Medical condition: Patients with 1° and 2° Raynaud’s phenomenon (RP)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002444-24 Sponsor Protocol Number: HS-18-638 Start Date*: 2020-02-18
    Sponsor Name:Camurus AB
    Full Title: An Exploratory Trial Assessing Vascular Digital Perfusion, Pharmacokinetics, Safety and Tolerability Following a Single Dose of CAM2043 (Treprostinil Subcutaneous Depot) in Patients with Raynaud’s ...
    Medical condition: Raynaud’s phenomenon secondary to systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-002774-64 Sponsor Protocol Number: HP 3.1 Start Date*: 2007-12-04
    Sponsor Name:Deutsches Herzzentrum Berlin, Kompetenznetz Angeborene Herzfehler
    Full Title: Therapy of PAH – Treatment with Sildenafil in Eisenmenger Patients
    Medical condition: Patients with pre-existing congenital heart disease may develop Eisenmenger physiology (EP), characterized by development of pulmonary arterial hypertension and intracardiac right to left shunt. Th...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000634-35 Sponsor Protocol Number: ALT-OXI-2018 Start Date*: 2018-10-31
    Sponsor Name:Althaia Xarxa Assistencial Universitària de Manresa. Fundació Privada.
    Full Title: HIGH-FLOW NASAL CANNULA THERAPY AS AN ADJUVANT IN THE TREATMENT OF SEVERE SEPSIS. A Multicenter parallel-group randomized clinical trial.
    Medical condition: Patients > 18 yr. with diagnostic criteria for severe sepsis, within 6 hours of admission in the Emergency Room, defined as hypotension after hemodynamic resuscitation, initial lactate > 4, or pers...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000021-57 Sponsor Protocol Number: 01000 Start Date*: 2006-03-10
    Sponsor Name:Rigshospitalet
    Full Title: Bosentan and Sildenfil for patients with Eisenmenger syndrome
    Medical condition: Eisenmengers syndrome is condition with severe pulmonary arterial hypertension due to a shunting of blood from the left side of the heart to the right side of the heart. When the pressure in the pu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-003203-35 Sponsor Protocol Number: VP-C21-004 Start Date*: 2019-12-13
    Sponsor Name:Vicore Pharma AB
    Full Title: A Phase 2, single-center, randomised, double-blind, placebo-controlled, cross-over, cold challenge study investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud’s ...
    Medical condition: Systemic sclerosis (SSc) Raynaud’s phenomenon (RP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10037912 Raynaud's phenomenon PT
    21.0 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2005-000489-37 Sponsor Protocol Number: SURF-04-01 Start Date*: 2005-08-26
    Sponsor Name:Nektar Therapeutics
    Full Title: An open label, randomized, controlled study to evaluate the safety and efficacy of aerosolized surfactant, Curosurf®, delivered via nasal continuous positive airway pressure pulmonary drug delivery...
    Medical condition: The medical condition for this application is the Respiratory Distress Syndrome (RDS). RDS, also known as hyaline membrane disease, is characterized by lung immaturity and surfactant deficiency a...
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002569-37 Sponsor Protocol Number: APHP180584 Start Date*: 2020-05-13
    Sponsor Name:Assistance Publique Hôpitaux de Paris
    Full Title: Empirical steroids and/or antifungals in immunocompromised patients with acute respiratory failure from undetermined etiology: a multicenter double-blind randomized controlled trial
    Medical condition: immunocompromised patients with acute respiratory failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005723-20 Sponsor Protocol Number: RC31/20/0445 Start Date*: 2022-02-10
    Sponsor Name:CHU de Toulouse
    Full Title: Evaluation of Botulinum TOXin type A in the treatment of Buerger’s disease
    Medical condition: This study assesses the feasibility and safety of treatment with botulinum toxin injection in patients with Buerger's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002876-41 Sponsor Protocol Number: 38RC18.123 Start Date*: 2019-03-27
    Sponsor Name:CHU Grenoble-Alpes
    Full Title: Assesment of Propofol sedation during intra tracheal surfactant administration by the LISA method (Less Invasive Surfactant Administration)
    Medical condition: Respiratory Distress Syndrome of preterm babies born < 32 weeks of gestational age
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004979-37 Sponsor Protocol Number: 06-004 Start Date*: 2006-10-27
    Sponsor Name:MediQuest Therapeutics, Inc.
    Full Title: Phase III “In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon
    Medical condition: Moderate to severe primary Raynaud’s, OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as scleroderma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000290-37 Sponsor Protocol Number: PVP-2016003 Start Date*: 2018-11-21
    Sponsor Name:Provepharm SAS
    Full Title: Open label clinical study to evaluate the safety and efficacy of ProvayBlueTM (methylene blue) for the treatment of acquired methemoglobinemia
    Medical condition: Acquired methemoglobinemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012871 10054290 Acquired methemoglobinemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-002023-11 Sponsor Protocol Number: 53718678RSV3001 Start Date*: 2021-02-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) DE (Prematurely Ended) SE (Completed) CZ (Completed) HU (Completed) BE (Completed) PL (Completed) Outside EU/EEA EE (Completed) LV (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003642-93 Sponsor Protocol Number: 53718678RSV2002 Start Date*: 2018-12-05
    Sponsor Name:Janssen Sciences Ireland UC
    Full Title: A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses o...
    Medical condition: Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10066740 Acute respiratory tract infection LLT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Prematurely Ended) HU (Completed) SE (Completed) FR (Completed) DE (Prematurely Ended) PL (Completed) BG (Completed) Outside EU/EEA IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023668-42 Sponsor Protocol Number: CRI 102194 Start Date*: 2011-02-03
    Sponsor Name:Southampton University Hospital NHS Trust
    Full Title: Pulmonary surfactant (S) biology in ventilated children on a paediatric intensive care unit with acute (A) hypoxic respiratory (R) failure- a pilot (P) study (S): (SARPS)
    Medical condition: acute hypoxic respiratory failure in children ventilated on paediatric intensive care
    Disease: Version SOC Term Classification Code Term Level
    12.1 10040047 Sepsis PT
    12.1 10018985 Haemorrhage intracranial PT
    12.1 10006093 Bradycardia PT
    12.1 10021097 Hypotension PT
    12.1 10006475 Bronchopulmonary dysplasia PT
    12.1 10035759 Pneumothorax PT
    12.1 10037394 Pulmonary haemorrhage PT
    12.1 10058490 Hyperoxia PT
    12.1 10011705 Cyanosis neonatal PT
    12.1 10002974 Apnoea PT
    12.1 10033318 Oxygen saturation decreased PT
    12.1 10014408 Electroencephalogram abnormal PT
    12.1 10063349 Endotracheal intubation complication PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-024005-13 Sponsor Protocol Number: 3098009 Start Date*: 2011-03-11
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Efficacy of ORM-12741 for prevention of cold-induced vasospasm; a randomised, double-blind, placebo-controlled, single centre crossover study in patient with Raynaud's phenomenon secondary to syste...
    Medical condition: Raynaud's phenomenon secondary to systemic sclerosis (Raynaud's syndrome)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10037914 Raynaud's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004482-14 Sponsor Protocol Number: P160917 Start Date*: 2019-08-14
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
    Full Title: Tocolysis in the management of preterm premature rupture of membranes before 34 weeks of gestation: a double-blinded randomized controlled trial
    Medical condition: Pregnant women with PPROM at 22 to 33 weeks gestation
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003846-10 Sponsor Protocol Number: MJIP1.0 Start Date*: 2024-05-02
    Sponsor Name:Fakultní nemocnice Plzeň
    Full Title: A pilot study comparing the haemodynamic effects and safety of an intravenous fluid bolus of 0.5M sodium lactate against 3% saline in patients with septic shock
    Medical condition: Septic shock fluid treatment
    Disease: Version SOC Term Classification Code Term Level
    26.0 10021881 - Infections and infestations 10040580 Shock septic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:17:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA